A Case Report of Familial Chylomicronemia Syndrome With Infantile Onset: One‐Year Follow‐Up on Lipid Profile and Growth Development Authors: Jinyi Liu, Xuanyu Meng, Yi Wu, Guosheng Huang, Shuheng Liang Published: 2026 ABSTRACT ABSTRACTFamilial chylomicronemia syndrome (FCS) is a rare autosomal recessive disease caused by a biallelic loss‐of‐function mutation in the lipoprotein lipase (LPL) gene or its cofactors. This case report describes the diagnosis, management, and one‐year follow‐up of an infant with FCS. The patient presented in early infancy with severe hypertriglyceridemia. Diagnosis was confirmed by genetic testing, which revealed a compound heterozygous mutation in the LPL gene. Management centered on a strict low‐fat diet with medium‐chain triglyceride (MCT) supplementation. Over a one‐year follow‐up period, significant improvements in triglyceride levels and catch‐up growth were observed, highlighting the critical importance of early diagnosis and dietary intervention.Keywords: familial chylomicronemia syndrome, hypertriglyceridemia, infant, lipoprotein lipase, medium chain triglyceride Introduction Familial chylomicronemia syndrome (FCS; OMIM: 238600), also known as primary hyperlipoproteinemia type I (T1HLP) or Lipoprotein lipase deficiency (LPLD), is a rare autosomal recessive genetic disease defined by severe hypertriglyceridemia and accumulation of chylomicrons in fasting plasma. Recurrent, severe pancreatitis is a potentially fatal complication. The incidence of homozygous cases is approximately one in 1 million, and heterozygous cases one in 500 [1]. There are variants in five major genes causing FCS: lipoprotein lipase (LPL), apolipoprotein CII (APOC2), lipase maturation factor 1 (LMF1), glycosyl‐phosphatidylinositol anchored high‐density lipoprotein‐binding protein 1 (GPIHBP1), and apolipoprotein AV (APOA5) [2, 3]. Among these, about 80%–90% of FCS patients have bi‐allelic mutations in the LPL gene [4]. In addition to the above gene mutations, LPL‐antibodies and GPIHBP1 autoantibodies can also cause hypertriglyceridemia [5, 6, 7], and there may be undiscovered mutated genes as well [8]. In the current study, we describe the clinical manifestations, diagnosis, treatment, and one‐year follow‐up of a severely hypertriglyceridemic infant caused by a compound heterozygous mutation of the LPL gene. Case Presentation Medical History The proband, a 41‐day‐old Chinese female infant, was admitted to the hospital with the complaint of “half a month of hematochezia”. She was the first child of non‐consanguineous parents, delivered vaginally at full term with uneventful antenatal and perinatal histories. Her birth weight was 2640 g (z‐score: −1.37) and there was no history of resuscitation for asphyxia or phototherapy for jaundice. Both parents were in good health and denied any family history of hereditary diseases. After birth, she was fed a combination of breast milk and formula milk. Half a month ago, the first bloody stool was found (Figure 1A). No blood tests were taken at another hospital, and she was treated with oral probiotics, but there was no significant improvement. Physical examination revealed normal vital signs, a length of 55 cm (z‐score: 0.38), and a weight of 4.0 kg (z‐score: −0.95). There were no dysmorphic features, but her complexion was a little pale. There were mild eruptive xanthomas on the neck and back, with no bleeding points and eczema. Cardiopulmonary examination showed no abnormality. The abdomen was soft without hepatosplenomegaly. The blood sample appeared as a rare pink suspension, which was separated into two layers after centrifugation: the upper layer was a milky, oily substance, and the lower layer consisted of red blood cells (Figure 1B). Laboratory examination showed the following results: white blood cell (WBC) count 16.4*109/L, hemoglobin (HB) 86 g/L, eosinophils 11.6% (reference range 1.0%–10.0%), total cholesterol (TC) 35.32 mmol/L (reference range 3.1–5.7 mmol/L), triglycerides (TG) 337.72 mmol/L (reference range 0.56–1.71 mmol/L), high‐density lipoprotein cholesterol (HDL) 2.14 mmol/L (0.78–2.0 mmol/L), and low‐density lipoprotein cholesterol (LDL) 15.73 mmol/L (2.06–3.10 mmol/L). Amylase and lipase were still within the normal range. Blood gas analysis, lactic acid levels, liver function tests, kidney function tests, myocardial enzymes, electrolytes, stool routine, urine routine were all normal. Stool culture was negative. Ultrasonography of liver, bile ducts, pancreas, spleen, urinary system, adrenal gland, heart, and chest were normal. Fundus examination revealed no evidence of lipemia retinalis. At the same time, we also examined the blood lipid levels of the parents. Her father's lipid profile showed TG of 2.05 mmol/L, with other parameters normal, and her mother had normal blood lipids. (A) The first episode of bloody stool, seemed to be pink‐colored; (B) The blood sample showed pinkish in color on admission, and a creamy layer on top after centrifugation; (C) After the treatment, the color of the blood changed from pink to red, but a creamy layer could still be observed after centrifugation. Diagnosis Hyperchylomicronemia was highly suspected. After obtaining informed consent, peripheral blood samples from the proband and her parents were collected for Whole exome sequencing (WES) and Sanger sequencing. The WES results revealed compound heterozygous mutations in exon 8 of the LPL gene (NM_000237.3): c.809G>A(p.Arg270His) and c.899_921dup(p.Asn308fs*4) in the proband's peripheral blood DNA (Figure 2). The LPL p.Arg270His missense variant was inherited from her father and the p.Asn308fs*4 frameshift mutation was inherited from her mother. Both mutations were classified as ‘pathogenic’ according to American College of Medical Genetics and Genomics (ACMG) criteria. The diagnosis of familial chylomicronemia syndrome was confirmed by genetic testing. Sanger sequencing (LPL, NM_000237.3): C.809G>A (p. Arg270His); c.899_921dup (p. Asn308fs*4). Treatment The infant was fasted for 3 days and given intravenous fluids. Blood lipid levels were checked again on the 4th day: TC was 46.61 mmol/L and TG 286.41 mmol/L. On the fifth day, she was fed a low‐fat diet (fat energy ratio approximately 20%). Due to the higher cost and procurement difficulties, the family did not choose a high‐MCT formula such as monogen (which contains 2.2 g of fat per 100 mL with 84% MCT). Instead, we chose an MCT‐rich extensively hydrolyzed formula, Pepti‐Junior (which contains 3.5 g of fat per 100 mL with 52% MCT), and maltodextrin was added to reduce daily fat intake. The ratio was adjusted according to weight and caloric needs, with dietary fat intake restricted to less than 20% of total energy. Owing to the high LCT content, breast milk was discontinued. After 1 week on the low‐fat diet, the color of the blood reverted to red, but white oil was still visible after centrifugation (Figure 1C). TC was 7.11 mmol/L, and TG was 11.09 mmol/L. She was discharged after 11 days. Follow‐Up After discharge, the infant was followed up regularly to monitor growth, development, and blood lipids. The fat energy ratio was limited to less than 20%. An additional supply of fat‐soluble vitamins such as vitamin A and vitamin D was given every day. After the age of 6 months, rice porridge, vegetable puree, lean meat puree, and MCT oil were gradually introduced. At the last follow‐up, she was 1 year old, with a length of 74 cm (z‐score: 0.13) and weight of 8.6 kg (z‐score: −0.38). She did not suffer from any symptoms such as vomiting, bloating, diarrhea, hematochezia, or crying restlessness. Physical examination did not reveal pallor, edema, xanthomas, hepatosplenomegaly, or other abnormalities. Laboratory tests revealed that TC was 2.69 mmol/L and TG was 7.67 mmol/L (Figure 3); blood amylase, lipase, glucose, hemoglobin, and albumin were all within the normal range. However, fundus re‐examination and liver ultrasonography were refused by her parents. After 1 year of follow‐up, she didn't suffer from acute pancreatitis, and her growth parameters, motor development, and cognitive development remained within the normal range (Figure 4). The curves of TC and TG after the infant was discharged from the hospital (the first set of data represents the lipid levels at the time of discharge). TG: 1 mol/L = 88.5 mg/dL. The growth curve charts of this infant (weight‐for‐age and length‐for‐age). Discussion Chylomicrons (CM) in the plasma of healthy individuals are completely cleared after 12 h fasting, so there is almost no CM in their plasma. However, in patients with familial chylomicronemia syndrome (FCS), due to the lack of functional LPL (e.g., LPL gene mutation) or its co‐factors, the clearance of CM from plasma is impaired, leading to the accumulation of triglycerides (TG) in plasma. Therefore, pink‐colored or milky blood is often a suspicious clue and a characteristic manifestation of FCS. FCS usually manifests in early childhood, with 25% occurring during infancy [3, 9], and a few cases are discovered incidentally in the neonatal period [9, 10, 11, 12]. Common symptoms of FCS are abdominal pain, recurrent episodes of pancreatitis, eruptive xanthomas, dyspnea, hepatosplenomegaly, and lipemia retinalis [3, 13], however, the presentation can be heterogeneous in infancy and may include other signs such as pallor, anemia, jaundice, vomiting, irritability, hematuria, and diarrhea, or may present only with a positive family history [1, 14, 15, 16, 17]. The infant in this case presented with hematochezia, which is atypical. A high concentration of chylomicrons may increase blood viscosity and cause intestinal vascular damage, resulting in necrosis and gastrointestinal hemorrhage. First, intestinal infection, obstruction, and intussusception must be excluded. Complete blood count, routine stool examination, stool culture, abdominal X‐ray, and gastrointestinal ultrasound did not indicate infection, obstruction, or intussusception. Second, food protein‐induced proctocolitis (FPIP) needed to be considered. The infant was fed with a mixture of breast milk and cow's milk. After fasting or feeding with extensively hydrolyzed formula (eHF), the hematochezia disappeared; therefore, FPIP cannot be excluded. However, the gold standard for the diagnosis of cow's‐milk protein allergy (CMPA) is the experimental dietary avoidance‐oral food challenge (EDA‐OFC) [18, 19]. Considering that conventional formula milk powder is mainly composed of long‐chain triglycerides (LCT) and has a lower content of medium‐chain triglycerides (MCT), OFC was not performed after 2 weeks. The primary therapeutic goal for FCS management is the prevention of pancreatitis episodes. Healthy TG levels are consistently defined as < 1.7 mmol/L. A TG level above 1000 mg/dL (11.3 mmol/L) is often regarded as severe hypertriglyceridaemia (SHTG) [20]. Experts recommend maintaining the plasma TG levels below 500–1000 mg/dL to prevent pancreatitis [3]. Immediate management included fasting and intravenous hydration. Therapeutic plasma exchange has been shown to rapidly lower plasma triglycerides [21], including in some cases of infantile FCS [22, 23]. However, there is no standard for determining whether plasmapheresis is needed. Most hospitals lack plasma exchange equipment for infants, and puncturing the femoral vein, internal jugular vein, and subclavian vein is difficult and risky in infants. Therefore, performing plasma exchange in infants under 3 months of age or newborns is challenging. In this case, the triglyceride was nearly 200 times higher than normal. Given the risks of the puncture procedure and the absence of organ damage, plasmapheresis was not performed. Once the acute risk was controlled, the patient was gradually transitioned to a very low‐fat diet to prevent long‐term complications. A very‐low‐fat diet, defined as either consuming less than 15–20 g of fat per day or restricting total dietary fat to less than 10%–15% of total daily caloric intake, was recommended in dietary guidelines for FCS [24, 25]. As MCTs are not incorporated into chylomicrons and are absorbed directly from the portal vein, they are used to replace some of the dietary LCT for these patients. A special low‐fat, low‐LCT, high‐MCT formula or skimmed and fortified expressed breast milk is recommended for infant FCS [25]. The efficacy of dietary therapy in reducing TG levels has been confirmed in two single‐center retrospective case studies [26, 27]. Our modified diet (MCT‐rich formula with maltodextrin added) is suitable for infants under 6 months old who have not yet started complementary foods. It is economical and convenient, but reducing the fat energy ratio to below 15% is extremely difficult because it would result in a very low protein intake, which is not conducive to the growth and development of the infant. We initially did not limit the fat energy ratio to below 15%, but rather to no more than 20%. As a result, the triglyceride levels fluctuated around 11.3 mmol/L, which is prone to causing acute pancreatitis [4]. Fortunately, our infant did not suffer from pancreatitis. Later, with the guidance of a nutritionist, low‐fat complementary foods (such as rice paste, vegetable puree, lean meat puree, etc.) and MCT oil were added after the infant turned 6 months old. The fat energy ratio gradually approached 15%, and the concentration of triglycerides further decreased. Although there was concern about fat‐soluble vitamin and essential fatty acid deficiencies due to the low‐fat diet, such deficiencies were not observed. Another unexpected finding was that despite the relatively low protein intake, the infant did not suffer from malnutrition or hypoproteinemia. In the first year, the infant achieved a balance between living on a strict diet for disease management and ensuring appropriate nutritional intakes for growth and development. Notably, despite the severe hypertriglyceridemia at presentation, the infant did not exhibit failure to thrive during the one‐year follow‐up, which further supports the effectiveness of early dietary intervention. Several cases of FCS that occurred in infancy have been reported in the literature. With only a simple low‐fat diet, blood lipid levels were controlled until adulthood [25, 28]. Challenges include maintaining dietary compliance as the child ages, ensuring adequate essential fatty acid intake, and monitoring for psychosocial impacts. Conventional triglyceride‐lowering therapies (such as statins, fibrates, niacin and omega‐3 fatty acids) are largely ineffective for patients with FCS. New targeted drugs (such as apolipoprotein C‐III inhibitors or ANGPTL3 inhibitors) offer significant potential, but long‐term studies are needed to confirm their efficacy and safety in FCS patients [29]. Novel therapies like gene therapy (e.g., LPL gene replacement) have been discussed as future possibilities. It is believed that in the near future, the application of gene therapy will be able to alleviate extreme dietary restrictions and create opportunities for a normal diet and psychological development. Conclusion Early recognition, genetic confirmation, and immediate implementation of a strict low‐fat, MCT‐supplemented diet are pivotal in the management of infantile‐onset FCS. This strategy can effectively mitigate acute complications, particularly pancreatitis, and enable normal growth and neurodevelopment, as evidenced by the favorable one‐year outcome in this infant. Long‐term, multidisciplinary follow‐up is essential for managing this genetic metabolic disease. Author Contributions Jinyi Liu: conceptualization, formal analysis, methodology, resources, writing – original draft, writing – review and editing. Xuanyu Meng: conceptualization, data curation, formal analysis, funding acquisition, investigation, methodology. Yi Wu: investigation, methodology, project administration, resources, software, supervision. Guosheng Huang: data curation, formal analysis, software, supervision, visualization. Shuheng Liang: investigation, methodology, project administration, visualization, writing – review and editing. Funding The authors have nothing to report. Ethics Statement This study was conducted in accordance with the principles of the Declaration of Helsinki. This study was reviewed and approved by the Ethics Committee of the Maternal and Child Health Hospital in Guangxi Zhuang Autonomous Region (approval No. 2022‐2‐30). All procedures were conducted in accordance with relevant ethical guidelines and regulations to ensure the confidentiality and protection of participants' data. Consent Written informed consent to participate was obtained from the parents. Conflicts of Interest The authors declare no conflicts of interest.